View in EDS HTML Full Text PDF Full Text

A Phase I Study of the Anti-CEACAM6 Antibody Tinurilimab (BAY 1834942) in Patients with Advanced Solid Tumors.

Saved in:
Bibliographic Details
Title: A Phase I Study of the Anti-CEACAM6 Antibody Tinurilimab (BAY 1834942) in Patients with Advanced Solid Tumors.
Authors: Siu LL; Princess Margaret Cancer Centre, University Health Network, University of Toronto, 700 University Avenue, Suite 7-624, Toronto, M5G 1Z5, Canada. lillian.siu@uhn.ca., Hong DS; The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Döcke WD; Bayer AG, Berlin, Germany., Tetzner R; Bayer AG, Berlin, Germany., Trautwein M; Bayer AG, Wuppertal, Germany., Phelps C; Bayer HealthCare Pharmaceuticals, Inc., Whippany, NJ, USA., Willuda J; Bayer AG, Berlin, Germany., Yu XQ; Bayer HealthCare Pharmaceuticals, Inc., Whippany, NJ, USA., Nogai H; Bayer Consumer Care, Basel, Switzerland.; Ryvu Therapeutics, Krakow, Poland., Johnson M; Drug Development Unit, Sarah Cannon Research Institute at Tennessee Oncology, Nashville, TN, USA., Goh BC; National University Cancer Institute and National University Hospital and Cancer Science Institute, National University of Singapore, Singapore, Singapore.
Source: Targeted oncology [Target Oncol] 2025 Jul; Vol. 20 (4), pp. 637-649. Date of Electronic Publication: 2025 Jun 04.
Publication Type: Journal Article; Clinical Trial, Phase I
Journal Info: Publisher: Springer-Verlag France Country of Publication: France NLM ID: 101270595 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1776-260X (Electronic) Linking ISSN: 17762596 NLM ISO Abbreviation: Target Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 40465170
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: A Phase I Study of the Anti-CEACAM6 Antibody Tinurilimab (BAY 1834942) in Patients with Advanced Solid Tumors.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Siu+LL%22">Siu LL</searchLink>; Princess Margaret Cancer Centre, University Health Network, University of Toronto, 700 University Avenue, Suite 7-624, Toronto, M5G 1Z5, Canada. lillian.siu@uhn.ca.<br /><searchLink fieldCode="AU" term="%22Hong+DS%22">Hong DS</searchLink>; The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Döcke+WD%22">Döcke WD</searchLink>; Bayer AG, Berlin, Germany.<br /><searchLink fieldCode="AU" term="%22Tetzner+R%22">Tetzner R</searchLink>; Bayer AG, Berlin, Germany.<br /><searchLink fieldCode="AU" term="%22Trautwein+M%22">Trautwein M</searchLink>; Bayer AG, Wuppertal, Germany.<br /><searchLink fieldCode="AU" term="%22Phelps+C%22">Phelps C</searchLink>; Bayer HealthCare Pharmaceuticals, Inc., Whippany, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Willuda+J%22">Willuda J</searchLink>; Bayer AG, Berlin, Germany.<br /><searchLink fieldCode="AU" term="%22Yu+XQ%22">Yu XQ</searchLink>; Bayer HealthCare Pharmaceuticals, Inc., Whippany, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Nogai+H%22">Nogai H</searchLink>; Bayer Consumer Care, Basel, Switzerland.; Ryvu Therapeutics, Krakow, Poland.<br /><searchLink fieldCode="AU" term="%22Johnson+M%22">Johnson M</searchLink>; Drug Development Unit, Sarah Cannon Research Institute at Tennessee Oncology, Nashville, TN, USA.<br /><searchLink fieldCode="AU" term="%22Goh+BC%22">Goh BC</searchLink>; National University Cancer Institute and National University Hospital and Cancer Science Institute, National University of Singapore, Singapore, Singapore.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101270595%22">Targeted oncology</searchLink> [Target Oncol] 2025 Jul; Vol. 20 (4), pp. 637-649. <i>Date of Electronic Publication: </i>2025 Jun 04.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase I
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer-Verlag+France%22">Springer-Verlag France </searchLink><i>Country of Publication: </i>France <i>NLM ID: </i>101270595 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1776-260X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2217762596%22">17762596 </searchLink><i>NLM ISO Abbreviation: </i>Target Oncol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40465170
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s11523-025-01154-4
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 637
    Titles:
      – TitleFull: A Phase I Study of the Anti-CEACAM6 Antibody Tinurilimab (BAY 1834942) in Patients with Advanced Solid Tumors.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Siu LL
      – PersonEntity:
          Name:
            NameFull: Hong DS
      – PersonEntity:
          Name:
            NameFull: Döcke WD
      – PersonEntity:
          Name:
            NameFull: Tetzner R
      – PersonEntity:
          Name:
            NameFull: Trautwein M
      – PersonEntity:
          Name:
            NameFull: Phelps C
      – PersonEntity:
          Name:
            NameFull: Willuda J
      – PersonEntity:
          Name:
            NameFull: Yu XQ
      – PersonEntity:
          Name:
            NameFull: Nogai H
      – PersonEntity:
          Name:
            NameFull: Johnson M
      – PersonEntity:
          Name:
            NameFull: Goh BC
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 07
              Text: 2025 Jul
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1776-260X
          Numbering:
            – Type: volume
              Value: 20
            – Type: issue
              Value: 4
          Titles:
            – TitleFull: Targeted oncology
              Type: main
ResultId 1